Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.54 |
| ▸ | GGT1 | P19440 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640035 | 0.90 | CFD (0.64) | CFDKDM4EHSD17B10PTGS1ALDH1A1 | |
| SCHEMBL6403165 | 0.89 | CFD (0.62) | CFDKDM4EHSD17B10PTGS1ALDH1A1 | |
| SCHEMBL16719156 | 0.88 | CFD (1.00) | CFDKDM4EHSD17B10PTGS1ALDH1A1 | |
| SCHEMBL6897255 | 0.87 | CFD (0.79) | CFDKDM4EHSD17B10PTGS1ALDH1A1 | |
| SCHEMBL18928203 | 0.86 | CFD (0.64) | CFDKDM4EHSD17B10PTGS1ALDH1A1 | |
| SCHEMBL8587088 | 0.86 | CFD (0.59) | CFDKDM4EHSD17B10PTGS1ALDH1A1 | |
| SCHEMBL3289850 | 0.85 | CFD (0.77) | CFDKDM4EHSD17B10PTGS1ALDH1A1 | |
| SCHEMBL7658382 | 0.84 | CFD (0.56) | CFDKDM4EPTGS1ALDH1A1TSHR | |
| SCHEMBL11556750 | 0.84 | CFD (0.74) | CFDKDM4EHSD17B10PTGS1ALDH1A1 | |
| SCHEMBL8587536 | 0.83 | CYP4F2 (0.63) | CFDKDM4EHSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148554-A1 | Anti-inflammatory and anti-thrombotic compounds and their compositions | ZHANG DON (US) | 2005-07-07 | — | — | US | disclosed |
| EP-0914307-B1 | ENZYMATICALLY REMOVABLE LINKERS FOR SOLID PHASE SYNTHESIS | BASF AG (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004062598-A2 | ANTI-INFLAMMATORY AND ANTI-THROMBOTIC COMPOUNDS AND THEIR COMPOSITIONS | BETA PHARMA, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-6271345-B1 | FOR SYNTHESIS OF ORGANIC COMPOUNDS, COMBINATORIAL CHEMISTRY | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | disclosed |
| US-6200981-B1 | FOR TREATING INFLAMMATORY DISEASES SUCH AS ASTHMA, INFLAMMATORY BOWEL DISEASE, PSORIASIS, RHEUMATOID ARTHRITIS, MYOCARDIAL ISCHAEMIA, CYSTIC FIBROSIS, ARTHEREOSCLEROSIS, RESTENOSIS, PERIDONTAL DISEASE, SEPTIC SHOCK, OSTEOARTHRITIS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148554-A1 | Anti-inflammatory and anti-thrombotic compounds and their compositions | PTGS1, PTGS2, PTGER1 | CFD 117/4885KDM4E 3180/4885HSD17B10 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.